Martí Del Moral A, Fortique F (2019).
Nutr Hosp. 36:939-49.
Serum phospholipid docosahexaenonic acid is associated with cognitive functioning during middle adulthood.
Muldoon MF, Ryan CM, Sheu L, et al. (2010).
J Nutr. 140:848-53.
n 3 fatty acid proportions in plasma and cognitive performance in older adults.
Dullemeijer C, Durga J, Brouwer IA, et al. (2007).
Am J Clin Nutr. 86:1479-85.
Omega-3 fatty acids for the treatment of depressive disorders in children and adolescents: a meta-analysis of randomized placebo-controlled trials.
Zhang L, Liu H, Kuang L, Meng H, Zhou X (2019).
Child Adolesc Psychiatry Ment Health. 13:36.
Omega-3 polyunsaturated fatty acid (PUFA) status in major depressive disorder with comorbid anxiety disorders.
Liu JJ, Galfalvy HC, Cooper TB, et al. (2013).
J Clin Psychiatry. 74:732-8.
Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression.
Sublette ME, Ellis SP, Geant AL, Mann JJ (2011).
J Clin Psychiatry. 72:1577-84.
Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial.
Kiecolt-Glaser JK, Belury MA, Andridge R, et al. (2011).
Brain Behav Immun. 25:1725-34.
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry.
Freeman MP, Hibbeln JR, Wisner KL, et al. (2006).
J Clin Psychiatry. 67:1954-67.
Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study.
Zanarini MC, Frankenburg FR (2003).
Am J Psychiatry. 160:167-9.
Bailes JE, Patel V (2014).
Mil Med. 179:112-6.
Depletion of brain docosahexaenoic acid impairs recovery from traumatic brain injury.
Desai A, Kevala K, Kim HY (2014).
PLoS One. 9(1):e86472.
Omega-3 fatty acids and traumatic neurological injury: from neuroprotection to neuroplasticity?
Michael-Titus AT, Priestley JV (2014).
Trends Neurosci. 37:30-8.
Vulnerability imposed by diet and brain trauma for anxiety-like phenotype: implications for post-traumatic stress disorders.
Tyagi E, Agrawal R, Zhuang Y, et al. (2013).
PLoS One. 8(3):e57945.
Lewis M, Ghassemi P, Hibbeln J (2013).
Am J Emerg Med. 31:273.e5-8.
Roberts L, Bailes J, Dedhia H, et al. (2008).
J Am Coll Surg. 207:276-83.
Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo- controlled trial.
Rodríguez C, García T, Areces D, Fernández E, García-Noriega M, Domingo JC (2019).
Neuropsychiatr Dis Treat. 15:1193-1209.
Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis.
Bloch MH, Qawasmi A (2011).
J Am Acad Child Adolesc Psychiatry 50:991-1000.